Top Medical News
5 days ago
Dehydroepiandrosterone supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.
19 Oct 2020
The selective PI3Kδ inhibitor seletalisib demonstrates clinical activity in patients with primary Sjögren’s syndrome (PSS) despite enrolment-related underpowering, as shown in phase II trial data.
16 Oct 2020
Although treatment with tumour necrosis factor inhibitors (TNFi) tends to be prolonged, it has been shown to be safe and effective in reactive arthritis (ReA), according to a study.
15 Oct 2020
A growing waistline increases the risk of incident low physical function in the following year among adults with knee osteoarthritis (OA), suggests a recent study. Maintaining waist circumference (WC) may prevent the development of low physical function.
15 Oct 2020
Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis, producing significant reduction in skin fibrosis, according to the results of a phase II trial.
Jairia Dela Cruz, 14 Oct 2020
Wearable activity trackers are feasible for collecting data on physical activity patterns that may be used to estimate gout flares, as shown in a study.
14 Oct 2020
Smoking cigarettes appears to increase the risk of systemic lupus erythematosus (SLE), suggests a recent study. In addition, sex and age do not contribute to the risk of SLE over time.
Elvira Manzano, 05 Aug 2020
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
Audrey Abella, 21 Jul 2020
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
Pearl Toh, 20 Jul 2020
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Audrey Abella, 20 Jul 2020
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Elaine Soliven, 15 Jul 2020
Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
Audrey Abella, 09 Jul 2020
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.